clinicalomicsprowebdirectory
Facebook
Linkedin
Twitter
News
Topics
Informatics
Molecular Dx
Patient Care
Oncology
Precision Medicine
Translational Research
Magazine
Browse Issues
Subscribe
Marketplace
Translational Research
Molecular Diagnostics
Oncology/Therapeutics
Healthcare Informatics
Subscribe
Get Inside Precision Medicine Magazine
Get Inside Precision Medicine eNewsletters
Multimedia
eBooks
Webinars
Summits
Learning Labs
Podcasts
Inside Precision Medicine Live
Search
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Create an account
Privacy Policy
Create an account
Welcome! Register for an account
your email
your username
A password will be e-mailed to you.
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Inside Precision Medicine
News
News & Features
GBM Organoids Models Patient Response to CAR-T Cell Therapy in Real…
News & Features
Discovery of Two Distinct Subtypes of MASH Offers Path for Personalized…
News & Features
Mantle Cell Lymphoma Patients May Not Need Stem Cell Transplant
News & Features
How Much Have We Impacted Cancer Deaths, and Through What?
News & Features
Beam Therapeutics Sickle Cell Base Editing Works, Not Cause of Patient…
Topics
Informatics
Molecular Dx
Patient Care
Oncology
Precision Medicine
Translational Research
Magazine
Browse Issues
Subscribe
Marketplace
Translational Research
Molecular Diagnostics
Oncology/Therapeutics
Healthcare Informatics
Subscribe
Get Inside Precision Medicine Magazine
Get Inside Precision Medicine eNewsletters
Multimedia
eBooks
Webinars
Summits
Learning Labs
Podcasts
Inside Precision Medicine Live
Inside Precision Medicine
Clinical OMICs Magazine Volume 7, Issue No. 4
Moderna
News & Features
Clinical OMICs Magazine Volume 7, Issue No. 4
August 19, 2020
0
Coronavirus
U.S. Commits an Additional $1.5B to Moderna’s COVID-19 Vaccine Effort
August 12, 2020
0
Coronavirus
Moderna’s Phase III COVID-19 Vaccine Trial Launched
July 28, 2020
0
Coronavirus
Moderna’s COVID-19 Vaccine Speeds to Phase III Trial After More Positive Data
July 15, 2020
0
News & Features
Vaxart’s COVID-19 Oral Vaccine Candidate Gets Boost from Operation Warp Speed
June 29, 2020
0
Coronavirus
Moderna’s Phase I COVID-19 Trial Posts Positive Interim Data
May 19, 2020
0
Coronavirus
Moderna Gets FDA Green Light for COVID-19 Vaccine Phase II Trial
May 8, 2020
0
Coronavirus
Moderna’s COVID-19 Vaccine Candidate Put on Fast Track with $483M from BARDA
April 17, 2020
0
Coronavirus
Moderna Charts Fast Track of SARS-CoV-2 Vaccine to Clinical Trials
Julianna LeMieux, PhD
March 26, 2020
0
Molecular Dx
mRNA Therapy Developer Moderna Raises $604M in Largest-Ever Biotech IPO
December 7, 2018
0
1
2
3
4
Page 4 of 4
Related Content
Beam Therapeutics Sickle Cell Base Editing Works, Not Cause of Patient Death
Microglia Linked to Alzheimer’s Identified
GSK Inks Multi-Year Deal Around Muna’s Spatial Multi-Omics Platform
Women Pay for AI-Enhanced Mammography
Inside Precision Medicine
![Messenger RNA (mRNA) therapy developer Moderna has raised at least $604.3 million in gross proceeds in the largest initial public offering for a biotech. [© Argus/Fotolia]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/2040.jpeg "mRNA Therapy Developer Moderna Raises $604M in Largest-Ever Biotech IPO")
